Summary On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes
of Health (NIH)–sponsored AIDS Clinical Trials Group (ACTG) published results from a …

Background Tuberculosis is usually treated with a 6-month rifampin-based regimen.
Whether a strategy involving shorter initial treatment may lead to similar outcomes is …

Background Rifapentine-based regimens have potent antimycobacterial activity that may
allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. Methods …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Background Shorter but effective tuberculosis treatment regimens would be of value to the
tuberculosis treatment community. High-dose rifampicin has been associated with more …

Background Treatment of latent Mycobacterium tuberculosis infection is an essential
component of tuberculosis control and elimination. The current standard regimen of …

Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of
tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course …

Background Tuberculosis regimens that are shorter and simpler than the current 6-month
daily regimen are needed. Methods We randomly assigned patients with newly diagnosed …

Background Providing evidence-based guidelines to inform public health service delivery for
Member States and other stakeholders is one of the core responsibilities of the World Health …

Background 3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily
rifampicin (4R) are recommended for tuberculosis preventive treatment. As these regimens …